Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

Shunsuke Nishino, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2024-205008

Published: 2024

Journal Articles

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Jotaro Yamamoto, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Shinsuke Takagi, Kazuya Ishiwata, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2024-201930

Published: 2024

Journal Articles

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Yuki Taya, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Go Yamamoto, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 7437.

https://doi.org/10.1182/blood-2024-208778

Published: 2024

Journal Articles

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Ryo Koizumi, Shinsuke Takagi, Aya Nishida, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Kazuya Ishiwata, Hisashi Yamamoto, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2024-203327

Published: 2024

Journal Articles

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4933.

https://doi.org/10.1182/blood-2024-210383

Published: 2024

Journal Articles

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Tatsuro Hirao, Hisashi Yamamoto, Mika Kuno, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2024) 144 (Supplement 1): 4920.

https://doi.org/10.1182/blood-2024-198879

Published: 2024

Journal Articles

Haploidentical Transplantation with Post-Transplant Cyclophosphamide Versus Single Cord Blood Transplantation for Adults with Relapsed/Refractory Malignant Lymphoma

Masashi Nishikubo, Yoshimitsu Shimomura, Yosuke Nakaya, Akihito Shinohara, Naoyuki Uchida, Nobuyuki Takayama, Hikaru Kobayashi, Yasufumi Uehara, Jun Ishikawa, Kazuya Ishiwata, Nobuhiro Hiramoto, Hideyuki Nakazawa, Fumihiko Ishimaru, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Eisei Kondo, Shinichi Kako

Blood (2023) 142 (Supplement 1): 3607.

https://doi.org/10.1182/blood-2023-178951

Published: 2023

Journal Articles

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Tomoyo Kubo, Hisashi Yamamoto, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 4917.

https://doi.org/10.1182/blood-2023-182732

Published: 2023

Journal Articles

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Shinsuke Takagi, Hisashi Yamamoto, Kazuya Ishiwata, Yuki Asano-Mori, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6931.

https://doi.org/10.1182/blood-2023-184637

Published: 2023

Journal Articles

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Futoshi Yoshino, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Atsushi Wake, Naoyuki Uchida, Go Yamamoto

Blood (2023) 142 (Supplement 1): 6191.

https://doi.org/10.1182/blood-2023-185447

Published: 2023

Journal Articles

Comparison of Non-Relapse Mortality after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation for Hematologic Disease

Kaito Harada, Junya Kanda, Masahiro Hirayama, Fumiya Wada, Naoyuki Uchida, Hirohisa Nakamae, Masatsugu Tanaka, Makoto Onizuka, Hiroyuki Ohigashi, Nobuaki Nakano, Takahiro Fukuda, Kazuya Ishiwata, Yumiko Maruyama, Tetsuya Eto, Fumihiko Ishimaru, Yoshiko Atsuta, Hideki Nakasone, Takashi Tanaka

Blood (2023) 142 (Supplement 1): 4905.

https://doi.org/10.1182/blood-2023-184821

Published: 2023

Journal Articles

The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Blood (2023) 142 (Supplement 1): 1048.

https://doi.org/10.1182/blood-2023-178905

Published: 2023

Journal Articles

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Otoya Watanabe, Hisashi Yamamoto, Kyosuke Yamaguchi, Kosei Kageyama, Daisuke Kaji, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Go Yamamoto, Atsushi Wake, Naoyuki Uchida

Blood (2023) 142 (Supplement 1): 7096.

https://doi.org/10.1182/blood-2023-188946

Published: 2023

Journal Articles

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Shinsuke Takagi, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD PhD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Naoyuki Uchida, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 5382.

https://doi.org/10.1182/blood-2019-129859

Published: 2019

Journal Articles

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

Yamamoto Hisashi, MD PhD, Naoyuki Uchida, MD PhD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Takashi Mitsuki, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Shinsuke Takagi, Yuki Asano-Mori, MD PhD, Go Yamamoto, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2019) 134 (Supplement_1): 2041.

https://doi.org/10.1182/blood-2019-130550

Published: 2019

Journal Articles

High-Dose Intravenous Immunoglobulin and Immunosuppressive Therapy Have Therapeutic Potential for Non-Infectious Myelopathy and Peripheral Neuropathy Following Cord Blood Transplantation

Michiho Ebihara, MD, Shinsuke Takagi, Yoshikazu Uesaka, MD PhD, Takashi Mitsuki, MD, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Yukako Koike, MD PhD, Shigeyoshi Makino, MD PhD, Akiko Yoneyama, MD PhD, Atsushi Wake, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2018-99-116308

Published: 2018

Journal Articles

Cord Blood Units Containing Lower CD34 + Cells (0.5 - 1.0 x 10 5 /kg) Could be Alternative Donor Candidates for Single-Unit Cord Blood Transplantation for Adults: A Retrospective Study of 421 Patients in a Single Institute

Shinsuke Takagi, Mitsuhiro Yuasa, MD, Naoyuki Uchida, MD PhD, Michiho Ebihara, MD, Takashi Mitsuki, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Yukako Koike, MD PhD, Shigeyoshi Makino, MD PhD, Akiko Yoneyama, MD PhD, Atsushi Wake, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2018) 132 (Supplement 1): 2089.

https://doi.org/10.1182/blood-2018-99-119827

Published: 2018

Journal Articles

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

Kazuya Ishiwata, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Aya Nishida, MD, Daisuke Kaji, MD, Shinsuke Takagi, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Akiko Yoneyama, MD PhD, Shigeyoshi Makino, MD PhD, Naoyuki Uchida, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2017) 130 (Supplement 1): 3223.

https://doi.org/10.1182/blood.V130.Suppl_1.3223.3223

Published: 2017

Journal Articles

Proportion of CD34+CD38- Leukemia Stem Cell Fraction Predicts Relapse Rate after Umbilical Cord Blood Transplantation in Acute Myeloid Leukemia with Adverse Karyotype

Shinsuke Takagi, Akiko Yoneyama, MD PhD, Naoyuki Uchida, MD PhD, Takashi Mitsuki, Mitsuhiro Yuasa, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, Aya Nishida, MD, Kazuya Ishiwata, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Yukako Koike, Atsushi Wake, MD PhD, Shigeyoshi Makino, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2017) 130 (Supplement 1): 5082.

https://doi.org/10.1182/blood.V130.Suppl_1.5082.5082

Published: 2017

Journal Articles

Possible Therapeutic Potential of Recombinant Human Soluble Thrombomoduline Alpha for the Treatment of SOS/VOD: A Retrospective Study in Toranomon Hospital

Shinsuke Takagi, MD PhD, Mitsuhiro Yuasa, MD, Naoyuki Uchida, MD PhD, Kyosuke Yamaguchi, MD, Kosei Kageyama, MD, Daisuke Kaji, MD, Yuki Taya, MD PhD, Aya Nishida, MD, Kazuya Ishiwata, MD, Hisashi Yamamoto, MD, Go Yamamoto, MD PhD, Yuki Asano-Mori, MD PhD, Atsushi Wake, MD PhD, Shigeyoshi Makino, MD PhD, Akiko Yoneyama, MD PhD, Koji Izutsu, MD PhD, Shuichi Taniguchi, MD PhD

Blood (2016) 128 (22): 5747.

https://doi.org/10.1182/blood.V128.22.5747.5747

Published: 2016

NARROW

Conditioning with Fludarabine, Myeloablative Doses of Busulfan, and Melphalan (Flu/Bu4/Mel) Achieves Comparable or Superior Outcomes to Conventional Myeloablative Conditioning in Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation

What Is the Optimal Dose of MMF in Single Cord Blood Transplantation?: A Single-Center Analysis of MMF Dosage for GVHD Prophylaxis and Its Impact on Outcomes

Retrospective Analysis of Single-Unit Umbilical Cord Blood Transplantation in Elderly Patients (Aged 65 Years and Older) with Predominantly High-Risk Myeloid Malignancies: A Single-Institution Study

Still You Hesitate to Use Ino?: Inotuzumab Ozogamicin Optimized Post-Transplant Outcomes in R/R Ph-Negative B-ALL

Single CBT As 2nd Allo-SCT Can be a Promising Therapeutic Strategy for Patients with Relapsed Hematopoietic Malignancies, Especially with Myeloid Neoplasms

Single Cord Blood Transplantation Strongly Inhibits Leukemia Relapse and Is Associated with Significantly Better Leukemia-Free and Overall Survival Than HLA-Matched Related Donor in Allo-HSCT for Patients with Acute Myeloid Leukemia in Non-Remission Status

Haploidentical Transplantation with Post-Transplant Cyclophosphamide Versus Single Cord Blood Transplantation for Adults with Relapsed/Refractory Malignant Lymphoma

Comparison of Myeloablative Conditioning with Cyclophosphamide and Total-Body Irradiation (Cy/TBI) Vs. Fludarabine, Melphalan, and Total-Body Irradiation (Flu/Mel/TBI) in Patients Undergoing Allogeneic Stem Cell Transplant for AML/ALL

Efficacy of Lisocabtagene Maraleucel for Relapsed or Refractory Aggressive B Cell Lymphoma in Our Hospital

Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Relapse or Refractory Peripheral T-Cell Lymphoma at Toranomon Hospital and Toranomon Hospital Kajigaya

Comparison of Non-Relapse Mortality after Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplant Cyclophosphamide Versus Single Umbilical Cord Blood Transplantation for Hematologic Disease

The HLA-B Leader MM Genotype Has a Negative Impact on Outcomes in HLA-B One Antigen Mismatched and HLA-B Matched Cord Blood Transplantation without Anti-Thymocyte Globulin: Analysis of the Japanese Society for Transplantation and Cellular Therapy

Single CBT As 2nd Allo-SCT Is Promising for Selected Patients with Relapsed Hematopoietic Malignancies

Direct Comparison of Long-Term Outcome of Allogeneic Transplantation for Myelofibrosis in Chronic and Leukemic Stage in a Single Institute

Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation

High-Dose Intravenous Immunoglobulin and Immunosuppressive Therapy Have Therapeutic Potential for Non-Infectious Myelopathy and Peripheral Neuropathy Following Cord Blood Transplantation

Cord Blood Units Containing Lower CD34 + Cells (0.5 - 1.0 x 10 5 /kg) Could be Alternative Donor Candidates for Single-Unit Cord Blood Transplantation for Adults: A Retrospective Study of 421 Patients in a Single Institute

Prospective Study of High Dose Foscarnet Prophylaxis for HHV-6 Related CNS Diseases in Cord Blood Transplantation for Adult Patients

Proportion of CD34+CD38- Leukemia Stem Cell Fraction Predicts Relapse Rate after Umbilical Cord Blood Transplantation in Acute Myeloid Leukemia with Adverse Karyotype

Possible Therapeutic Potential of Recombinant Human Soluble Thrombomoduline Alpha for the Treatment of SOS/VOD: A Retrospective Study in Toranomon Hospital

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only